[go: up one dir, main page]

WO2002030446A3 - Procede visant a reduire ou a prevenir la formation d'adherences post-chirurgicales - Google Patents

Procede visant a reduire ou a prevenir la formation d'adherences post-chirurgicales Download PDF

Info

Publication number
WO2002030446A3
WO2002030446A3 PCT/US2001/032044 US0132044W WO0230446A3 WO 2002030446 A3 WO2002030446 A3 WO 2002030446A3 US 0132044 W US0132044 W US 0132044W WO 0230446 A3 WO0230446 A3 WO 0230446A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrinogen
prevention
post
reduction
adhesion formation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/032044
Other languages
English (en)
Other versions
WO2002030446A2 (fr
Inventor
Heinz Redl
Reiner Spaethe
Manuela Simunek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to US10/399,223 priority Critical patent/US7198786B2/en
Priority to AU2002213195A priority patent/AU2002213195A1/en
Publication of WO2002030446A2 publication Critical patent/WO2002030446A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002030446A3 publication Critical patent/WO2002030446A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne un procédé visant à réduire ou à prévenir chez un patient la formation d'adhérences pendant ou après une intervention chirurgicale, qui consiste à administrer à la surface de la plaie une solution de fibrinogène à raison d'environ 0,025-0,25 ml fibrinogène/cm2 de la surface présentant un risque de former des adhérences ; l'utilisation de fibrinogène dans une préparation renfermant du fibrinogène selon une concentration comprise entre 20 et 80 mg/ml, destinée à réduire ou à prévenir la formation d'adhérences post-chirurgicales.
PCT/US2001/032044 2000-10-13 2001-10-12 Procede visant a reduire ou a prevenir la formation d'adherences post-chirurgicales Ceased WO2002030446A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/399,223 US7198786B2 (en) 2001-10-12 2001-10-12 Method for the reduction or prevention of post-surgical adhesion formation
AU2002213195A AU2002213195A1 (en) 2000-10-13 2001-10-12 Reduction or prevention of post-surgical adhesion formation with fibrinogen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24020000P 2000-10-13 2000-10-13
US60/240,200 2000-10-13

Publications (2)

Publication Number Publication Date
WO2002030446A2 WO2002030446A2 (fr) 2002-04-18
WO2002030446A3 true WO2002030446A3 (fr) 2003-07-24

Family

ID=22905541

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032044 Ceased WO2002030446A2 (fr) 2000-10-13 2001-10-12 Procede visant a reduire ou a prevenir la formation d'adherences post-chirurgicales

Country Status (2)

Country Link
AU (1) AU2002213195A1 (fr)
WO (1) WO2002030446A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8257438B2 (en) * 2005-04-12 2012-09-04 Warsaw Orthopedic, Inc. Methods and devices for preserving motion in an articulating prosthetic disc
EP2011524A1 (fr) * 2007-07-02 2009-01-07 Omrix Biopharmaceuticals Ltd. Colle de fibrine avec agent de visualisation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022312A1 (fr) * 1991-06-17 1992-12-23 Wadstroem Jonas Composition pour le traitement de tissus corporels, contenant de la fibrine ou du fibrogene et un polymere biodegradable et biocompatible
WO1999056797A1 (fr) * 1998-05-01 1999-11-11 Zymogenetics, Inc. Compositions d'adhesif tissulaire entierement recombinantes
WO2000071153A2 (fr) * 1999-05-19 2000-11-30 Bio & Bio Licensing Sa Medicament pour application locale, contenant du fibrinogene, de la thrombine, des transglutaminases et des inhibiteurs de protease
WO2000072852A1 (fr) * 1999-06-01 2000-12-07 Bristol-Myers Squibb Company Prevention d'adherences post-chirurgicales utilisant un scellement de monomere de fibrine
EP1157706A2 (fr) * 2000-05-22 2001-11-28 Aventis Behring GmbH Utilisation de colle tissulaire à base de fibrinogène pour la prévention d'adhérences de tissus

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022312A1 (fr) * 1991-06-17 1992-12-23 Wadstroem Jonas Composition pour le traitement de tissus corporels, contenant de la fibrine ou du fibrogene et un polymere biodegradable et biocompatible
WO1999056797A1 (fr) * 1998-05-01 1999-11-11 Zymogenetics, Inc. Compositions d'adhesif tissulaire entierement recombinantes
WO2000071153A2 (fr) * 1999-05-19 2000-11-30 Bio & Bio Licensing Sa Medicament pour application locale, contenant du fibrinogene, de la thrombine, des transglutaminases et des inhibiteurs de protease
WO2000072852A1 (fr) * 1999-06-01 2000-12-07 Bristol-Myers Squibb Company Prevention d'adherences post-chirurgicales utilisant un scellement de monomere de fibrine
EP1157706A2 (fr) * 2000-05-22 2001-11-28 Aventis Behring GmbH Utilisation de colle tissulaire à base de fibrinogène pour la prévention d'adhérences de tissus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARNOLD P.B.: "Evaluation of resorbable barriers for preventing surgical adhesions", FERTILITY AND STERILITY, vol. 73, no. 1, January 2000 (2000-01-01), pages 157 - 161, XP001134965 *
BAXTER: "Tisseel, two component fibrin sealant human vapor heated", PACKAGE INSERT, November 1997 (1997-11-01), XP002230273, Retrieved from the Internet <URL:http://www.baxter.ca/downloads/en/bioscience/tisseel_insert_6208110ek11.pdf> [retrieved on 20030206] *

Also Published As

Publication number Publication date
AU2002213195A1 (en) 2002-04-22
WO2002030446A2 (fr) 2002-04-18

Similar Documents

Publication Publication Date Title
WO2000057900A3 (fr) Facteur
MY121517A (en) Anticonvulsant derivatives useful in reducing blood glucose levels
WO2002053101A3 (fr) Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002019969A3 (fr) Acide (5-(2-hydroxy-4-chlorobenzoyl) aminovalerique et ses sels, compositions contenant l&#39;acide et ses sels pour acheminer des agents actifs
HK1043303A1 (zh) 阿朴嗎啡在用於治療男性器質性勃起功能障礙的藥物的製備中的應用
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l&#39;incontinence urinaire
EP0838225A3 (fr) Solution locale anesthétique aqueuse
WO1999049854A3 (fr) Utilisation de dexmedetomidine pour la sedation dans une unite de soins intensifs
SI1220670T1 (sl) Uporaba L-karnitina in njegovih alkanoil derivatov kot ozmotsko sredstvo za medicinske namene
NZ516290A (en) Substituted phenoxyacetic acids
PL338415A1 (en) Application of physiologically compatible vanadium compounds, salts and complexes
EP1440689A3 (fr) Traitement des troubles neurotiques
AU2001274908A1 (en) Use of citrate-containing dialysate for renal dialysis treatment
WO2001089494A8 (fr) Procede d&#39;administration d&#39;un bisphosphonate
AU2002253785A1 (en) Catheter and implants for the delivery of therapeutic agents to tissues
HK1049105A1 (zh) 磷酸二酯酶4抑制剂的使用方法
EP1285660A4 (fr) Compositions d&#39;apport complementaire de zinc destinees a une administration par voie orale
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
WO2002030445A3 (fr) Fibrinogene plus inhibiteur de fibrinolyse n&#39;agissant pas sur la plasmine pour reduire ou prevenir la formation d&#39;adherences
WO2002030446A3 (fr) Procede visant a reduire ou a prevenir la formation d&#39;adherences post-chirurgicales
WO2002043715A3 (fr) Utilisation de composes 1-phenyl-3-dimethylamino-propane pour traiter l&#39;incontinence urinaire
SE9902597D0 (sv) New use
WO2001060343A3 (fr) Utilisation d&#39;acide 2-methyl-thiazolidin-2,4-dicarboxylique (2-mtdc) et/ou de ses sels physiologiquement compabibles pour le traitement et/ou la prevention de cancers
AU2003257473A1 (en) Modified amino acid for the inhibition of platelet aggregation
WO2000040225A3 (fr) Inhibition de l&#39;activite du tnf

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10399223

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP